Milestone Alert: Can-Fite Completes Enrollment in Phase 3 Trial of Oral Piclidenoson for Psoriasis

Can-Fite BioPharma Ltd. has completed enrollment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis.